Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambu Weighing Options For CardioPump After Panel Votes Against Approval

This article was originally published in The Gray Sheet

Executive Summary

Ambu is considering its next step in pursuing U.S. marketing of the CardioPump, following a 6-3 vote against approval by FDA's Circulatory System Devices Panel at a June 29 meeting in Rockville, Maryland.

You may also be interested in...



CPR Device Trials Should Have Minimal Exclusion Criteria – FDA Panel

Cardiac arrest patient survival until hospital discharge is an appropriate clinical efficacy endpoint in studies of CPR-enhancing devices, according to FDA's Circulatory System Devices Panel

Big Win For EMA On Transparency

The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.

UsernamePublicRestriction

Register

MT010284

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel